Differential Splicing Generates New Transmembrane Receptor and Extracellular Matrix-related Targets for Antibody-based Therapy of Cancer

Cancer Genomics - Proteomics

Stefan Klostermann²  Ulrich H. Weidle²  Daniela Maisel²  Manfred Schmitt¹  Elisabeth H. Weiss³ 

[1] Klinikum rechts der Isar of the Technical University Munich, Munich, GermanyKlinikum rechts der Isar of the Technical University Munich, Munich, GermanyKlinikum rechts der Isar of the Technical University Munich, Munich, Germany;Roche Diagnostics, Division Pharma, Penzberg, GermanyRoche Diagnostics, Division Pharma, Penzberg, GermanyRoche Diagnostics, Division Pharma, Penzberg, Germany;Department of Biology II, Ludwig Maximillians University Munich, Planegg-Martinsried, GermanyDepartment of Biology II, Ludwig Maximillians University Munich, Planegg-Martinsried, GermanyDepartment of Biology II, Ludwig Maximillians University Munich, Planegg-Martinsried, Germany

关键词: Angiogenesis;    constitutive signalling;    exon deletion and insertion;    hallmarks of cancer;    immunocytokines;    neo-epitope(s);    tumor-specific targets;    tumor targeting;    therapeutic window;    review;   

DOI  :  

来源: Delinasios GJ CO

【 摘 要 】

Alternative splicing has been shown to be deregulated in cancer and a link to growth stimulation has been established. Here we describe transmembrane and extracellular matrix-related targets generated by alternative splicing with a restricted pattern of expression in normal tissues and a deregulated pattern of expression in cancer as possible targets for therapeutic intervention with antibody-related agents. We focus on isoforms of transmembrane and extracellular matrix proteins, such as CD44, Claudin 18, L1 cell adhesion molecule and epithelial cellular adhesion molecule, fibronectin, tenascin, osteopontin and versican as well as transmembrane tyrosine kinases, such as fibroblast growth factor receptors, epidermal growth factor receptor and receptor d’origin nantais.

【 授权许可】

Unknown